JP2005520779A5 - - Google Patents

Download PDF

Info

Publication number
JP2005520779A5
JP2005520779A5 JP2003511763A JP2003511763A JP2005520779A5 JP 2005520779 A5 JP2005520779 A5 JP 2005520779A5 JP 2003511763 A JP2003511763 A JP 2003511763A JP 2003511763 A JP2003511763 A JP 2003511763A JP 2005520779 A5 JP2005520779 A5 JP 2005520779A5
Authority
JP
Japan
Prior art keywords
clomiphene
pharmaceutically acceptable
trans
cis
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003511763A
Other languages
English (en)
Japanese (ja)
Other versions
JP4845165B2 (ja
JP2005520779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/021524 external-priority patent/WO2003005954A2/en
Publication of JP2005520779A publication Critical patent/JP2005520779A/ja
Publication of JP2005520779A5 publication Critical patent/JP2005520779A5/ja
Application granted granted Critical
Publication of JP4845165B2 publication Critical patent/JP4845165B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003511763A 2001-07-09 2002-07-09 男性におけるテストステロン欠損の処置のための方法および物質 Expired - Fee Related JP4845165B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30431301P 2001-07-09 2001-07-09
US60/304,313 2001-07-09
PCT/US2002/021524 WO2003005954A2 (en) 2001-07-09 2002-07-09 Methods and materials for the treatment of testosterone deficiency in men

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009204154A Division JP2009280623A (ja) 2001-07-09 2009-09-03 男性におけるテストステロン欠損の処置のための方法および物質

Publications (3)

Publication Number Publication Date
JP2005520779A JP2005520779A (ja) 2005-07-14
JP2005520779A5 true JP2005520779A5 (enExample) 2006-01-05
JP4845165B2 JP4845165B2 (ja) 2011-12-28

Family

ID=23175972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003511763A Expired - Fee Related JP4845165B2 (ja) 2001-07-09 2002-07-09 男性におけるテストステロン欠損の処置のための方法および物質
JP2009204154A Withdrawn JP2009280623A (ja) 2001-07-09 2009-09-03 男性におけるテストステロン欠損の処置のための方法および物質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009204154A Withdrawn JP2009280623A (ja) 2001-07-09 2009-09-03 男性におけるテストステロン欠損の処置のための方法および物質

Country Status (23)

Country Link
US (6) US7759360B2 (enExample)
EP (1) EP1411916B1 (enExample)
JP (2) JP4845165B2 (enExample)
KR (1) KR100851648B1 (enExample)
CN (2) CN1954807A (enExample)
AT (1) ATE406153T1 (enExample)
AU (1) AU2002318225B2 (enExample)
BR (1) BR0211067A (enExample)
CA (2) CA2453337C (enExample)
CL (1) CL2004000026A1 (enExample)
CO (1) CO5550428A2 (enExample)
CY (1) CY1108563T1 (enExample)
DE (1) DE60228583D1 (enExample)
DK (1) DK1411916T3 (enExample)
EC (1) ECSP044937A (enExample)
ES (1) ES2312593T3 (enExample)
MX (1) MXPA04000097A (enExample)
NZ (2) NZ530491A (enExample)
PL (1) PL211339B1 (enExample)
PT (1) PT1411916E (enExample)
RU (1) RU2297218C2 (enExample)
WO (1) WO2003005954A2 (enExample)
ZA (1) ZA200400142B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
CA2453337C (en) 2001-07-09 2012-08-28 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
MX2007000050A (es) * 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
KR20070100811A (ko) * 2005-02-04 2007-10-11 레프로스 쎄라피우틱스 아이엔씨. 남성불임의 치료를 위한 트랜스―클로미펜을 이용한 물질과치료방법
NZ560551A (en) * 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
WO2008157335A2 (en) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US20110118355A1 (en) * 2007-09-21 2011-05-19 Harry Fisch Treatment of migraine headaches using antiestrogens
ES2718912T3 (es) * 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales
WO2009052377A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
US20090215733A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
RU2474424C2 (ru) * 2010-09-24 2013-02-10 Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
CA2881604C (en) * 2011-08-09 2021-09-14 Kenneth W. Adams Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
SG10201704858PA (en) 2012-05-31 2017-07-28 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
AU2013306393A1 (en) * 2012-08-21 2015-02-19 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
EP2914268B1 (en) 2012-11-02 2018-07-04 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
CN104994877A (zh) 2012-11-02 2015-10-21 利普生物药剂公司 用于癌症治疗的反式-克罗米芬
US9814687B2 (en) * 2014-08-20 2017-11-14 Professional Compounding Centers Of America Transdermal pharmaceutical compositions including C-SERMs for low testosterone levels in men
RU2586305C1 (ru) * 2015-02-02 2016-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения обструктивной азооспермии и криптозооспермии у пациентов с хроническим простатитом
CN108463453A (zh) 2016-04-22 2018-08-28 意大利合成制造有限公司 用于制备具有针状晶体习性的柠檬酸恩氯米芬的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) * 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
JPH10501814A (ja) 1994-06-17 1998-02-17 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 生物的作用物質用のイン・シツゲル形成デリバリービヒクルおよびその使用方法
RU2089188C1 (ru) * 1994-07-13 1997-09-10 Владимир Александрович Божедомов Способ лечения мужского секреторного бесплодия
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
AU6824996A (en) * 1995-08-17 1997-03-12 Dyer, Alison Margaret Controlled release products
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
ES2565163T3 (es) * 1996-10-28 2016-03-31 General Mills, Inc. Imbibición y encapsulación de partículas de liberación controlada y producto encapsulado
IL132120A0 (en) * 1997-04-03 2001-03-19 Guilford Pharm Inc Biodegradable terephthalate polyester-poly (phosphate) polymers compositions articles and methods for making and using the same
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
DE69935335T2 (de) * 1998-08-07 2007-11-22 Novartis Vaccines and Diagnostics, Inc., Emeryville Pyrazole als modulatoren des östrogenrezeptors
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CO5180583A1 (es) * 1999-06-11 2002-07-30 Watson Pharmaceuticals Inc Administracion de esteroides androgenicos no orales a las mujeres
AU6132700A (en) * 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
US7067557B2 (en) 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CN100448487C (zh) * 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
CA2462081A1 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
CA2453337C (en) 2001-07-09 2012-08-28 Zonagen, Inc. Methods and materials for the treatment of testosterone deficiency in men
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1429779A2 (en) 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US6600110B1 (en) * 2001-10-01 2003-07-29 Gram Precision Portable digital readout scale
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) * 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
JP4312522B2 (ja) 2003-06-30 2009-08-12 株式会社リコー 現像剤補給方法、現像剤補給装置、及び、画像形成装置
MX2007000050A (es) 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
KR20070100811A (ko) 2005-02-04 2007-10-11 레프로스 쎄라피우틱스 아이엔씨. 남성불임의 치료를 위한 트랜스―클로미펜을 이용한 물질과치료방법
EP1853298A2 (en) * 2005-02-11 2007-11-14 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
NZ560551A (en) 2005-03-22 2010-02-26 Repros Therapeutics Inc Dosing regimes for trans-clomiphene
CN101309702A (zh) 2005-08-05 2008-11-19 雷普罗斯治疗公司 使用克罗米酚治疗女性不育症的方法及其组合物
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
ES2718912T3 (es) * 2007-10-16 2019-07-05 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de la diabetes en hombres hipogonadales
US20100111901A1 (en) * 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TW201500041A (zh) 2008-11-07 2015-01-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) * 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
CA2881604C (en) 2011-08-09 2021-09-14 Kenneth W. Adams Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males

Similar Documents

Publication Publication Date Title
JP2005520779A5 (enExample)
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
NZ610715A (en) Antiviral compounds and methods
WO2009046865A3 (en) Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent
WO2009040045A3 (en) Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
NO20062098L (no) Faststofftilstandmontelukast
WO2009043477A3 (en) Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent
CA2453337A1 (en) Methods and materials for the treatment of testosterone deficiency in men
WO2013016697A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
NO20032510D0 (no) Organiske forbindelser
EA200301165A1 (ru) Лекарственное средство на основе оксикодона
EP1159964A3 (en) Compositions and methods for stimulating gastrointestinal motility
CA2476201A1 (en) Modified release formulations of at least one form of tramadol
JP2002519434A5 (enExample)
JP2004516314A5 (enExample)
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
JP2003531118A5 (enExample)
WO2009033801A3 (en) Syndyphalin alone or in combination with antide as a therapeutic agent
CO5280073A1 (es) Composiciones
WO2009033712A3 (en) Use of melanotan ii as a therapeutic agent
WO2009033769A3 (en) Use of cortistatin 14 and others as a therapeutic agent
WO2009040051A3 (en) Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent
WO2009033791A3 (en) Use of a peptide as a therapeutic agent
JP2003503449A5 (enExample)
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser